A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy

Completed · Phase 1

Conditions studied: Glioma, Sarcoma

In brief

A dose escalation scale consisting of 5 dosage levels is being used to determine the maximum tolerated dose (MTD) of SU101. A minimum of 3 and a maximum of 6 patients will be enrolled at each dose level. MTD is defined as the dose level immediately below that at which 2 or more patients exhibit dose limiting toxicity. Each treatment cycle is 21 days. Patients receive a 96 hour continuous IV infusion of SU101 on days 1-4.

Key facts

Study ID
NCT00001573
Run by
National Cancer Institute (NCI)
People needed
30
Starts
1997-03-01
Expected to finish
2000-05-01
Last updated by the study team
2008-03-04

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.